Comparative Pharmacology
Head-to-head clinical analysis: CIDOFOVIR versus FAVLYXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIDOFOVIR versus FAVLYXA.
CIDOFOVIR vs FAVLYXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cidofovir is a nucleotide analog that inhibits viral DNA polymerase by competing with deoxycytidine triphosphate for incorporation into viral DNA, resulting in chain termination and inhibition of viral replication.
Acyclic nucleoside phosphonate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRP) by competing with adenosine triphosphate (ATP). It incorporates into nascent viral RNA causing chain termination after incorporation of the first 1-2 nucleotides.
5 mg/kg intravenously once weekly for 2 weeks, then 5 mg/kg every 2 weeks. Administer with probenecid 2 g orally 3 hours before dose, then 1 g at 2 and 8 hours after dose. Hydrate with 1 L normal saline before infusion.
200 mg orally twice daily for 10 days.
None Documented
None Documented
Clinical Note
moderateCidofovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cidofovir."
Clinical Note
moderateTenofovir disoproxil + Cidofovir
"Tenofovir disoproxil may decrease the excretion rate of Cidofovir which could result in a higher serum level."
Terminal elimination half-life is approximately 2.5 hours. However, the intracellular half-life of the active diphosphate metabolite is >48 hours, supporting once-weekly dosing.
Terminal elimination half-life approximately 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 24 hours in severe impairment).
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for approximately 90% of the administered dose. Biliary/fecal elimination is minimal (<5%).
Primarily renal excretion of unchanged drug (approx. 85%) with biliary/fecal elimination accounting for the remainder (approx. 15%).
Category D/X
Category C
Antiviral
Antiviral